All In Biotech

Free tool

FAERS Monitor: Eraxis

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021948 or its brand name (Eraxis, Anidulafungin). Reports on generic versions are filed under their own applications.

Reports

1,627

Serious

1,582

97% of reports

Hospitalization

779

Death reported

692

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective393
  • off label use187
  • multiple organ dysfunction syndrome174
  • septic shock128
  • sepsis118
  • pneumonia94
  • candida infection92
  • pyrexia92
  • neutropenia85
  • death80
  • drug resistance72
  • condition aggravated70
  • renal failure69
  • respiratory failure65
  • hypotension58

Reports by year received

View as table
YearReports
20068
200718
200812
200924
201036
201147
201228
201324
201422
201521
201652
201770
2018118
2019122
2020123
2021138
2022189
2023174
2024157
2025145
202699

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,532 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
multiple organ dysfunction syndromeSignal17479.969.413,412
candida infectionSignal9270.858.06,233
septic shockSignal12838.132.34,589
drug resistanceSignal7236.329.02,435
sepsisSignal11813.711.51,381
respiratory failureSignal6511.59.1616
neutropeniaSignal858.16.6524
renal failureSignal696.75.3332
drug ineffectiveSignal3933.93.5884
pneumoniaSignal943.83.1190
hypotensionSignal583.72.9115
pyrexiaSignal923.42.8159
condition aggravatedSignal703.02.491
off label useSignal1872.82.4217
death801.21.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.